A comparison of atropine sulfate and metaproterenol sulfate in the emergency treatment of asthma

J. P. Karpel, David W. Appel, D. Breidbart, M. J. Fusco

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Twenty-one patients presenting to an emergency room with moderate to severe asthma were entered into the following double-blind, crossover study. First, patients inhaled twice at 30-min intervals either atropine sulfate (AS) (3.2 mg and 3.2 mg; total dose, 6.4 mg) or metaproterenol sulfate (MP) (15 mg and 15 mg; total dose, 30 mg). Then after 80 min (crossover), they inhaled either AS (3.2 mg) or MP (15 mg). FEV1 was measured before treatment and at 30, 40, 70, 80, 110, and 120 min after the start of the study. FEV1 from 20 patients who completed the protocol were compared (Student's paired t test), and the values are presented as mean ± SEM. Both groups began with equally severe airways obstruction (AS versus MP: 1.02 ± 0.07 L and 0.92 ± 0.15 L, respectively; p > 0.05). After 120 min, when all had received both medications, FEV1 had improved significantly and similarly among both groups, indicating that initially they had equivalent bronchodilator capacities. Atropine sulfate produced small but significant changes in FEV1 at 30 and 70 min, but not at 80 min nor after crossover. In contrast, MP both alone and after crossover significantly improved FEV1. The difference in improvement among the groups was significant at 80 min and after crossover. Atopine sulfate produced multiple adverse effects in all patients. We conclude that during acute severe asthma, AS (6.4 mg) does not produce clinically significant bronchodilation either alone or in combination with MP.

Original languageEnglish (US)
Pages (from-to)727-729
Number of pages3
JournalAmerican Review of Respiratory Disease
Volume133
Issue number5
StatePublished - 1986

Fingerprint

Metaproterenol
Emergency Treatment
Atropine
Asthma
Bronchodilator Agents
Airway Obstruction
Double-Blind Method
Cross-Over Studies
Sulfates
Hospital Emergency Service
Students

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

A comparison of atropine sulfate and metaproterenol sulfate in the emergency treatment of asthma. / Karpel, J. P.; Appel, David W.; Breidbart, D.; Fusco, M. J.

In: American Review of Respiratory Disease, Vol. 133, No. 5, 1986, p. 727-729.

Research output: Contribution to journalArticle

@article{e1aa95212de34f9b8dd5d3f2c51d5b45,
title = "A comparison of atropine sulfate and metaproterenol sulfate in the emergency treatment of asthma",
abstract = "Twenty-one patients presenting to an emergency room with moderate to severe asthma were entered into the following double-blind, crossover study. First, patients inhaled twice at 30-min intervals either atropine sulfate (AS) (3.2 mg and 3.2 mg; total dose, 6.4 mg) or metaproterenol sulfate (MP) (15 mg and 15 mg; total dose, 30 mg). Then after 80 min (crossover), they inhaled either AS (3.2 mg) or MP (15 mg). FEV1 was measured before treatment and at 30, 40, 70, 80, 110, and 120 min after the start of the study. FEV1 from 20 patients who completed the protocol were compared (Student's paired t test), and the values are presented as mean ± SEM. Both groups began with equally severe airways obstruction (AS versus MP: 1.02 ± 0.07 L and 0.92 ± 0.15 L, respectively; p > 0.05). After 120 min, when all had received both medications, FEV1 had improved significantly and similarly among both groups, indicating that initially they had equivalent bronchodilator capacities. Atropine sulfate produced small but significant changes in FEV1 at 30 and 70 min, but not at 80 min nor after crossover. In contrast, MP both alone and after crossover significantly improved FEV1. The difference in improvement among the groups was significant at 80 min and after crossover. Atopine sulfate produced multiple adverse effects in all patients. We conclude that during acute severe asthma, AS (6.4 mg) does not produce clinically significant bronchodilation either alone or in combination with MP.",
author = "Karpel, {J. P.} and Appel, {David W.} and D. Breidbart and Fusco, {M. J.}",
year = "1986",
language = "English (US)",
volume = "133",
pages = "727--729",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "5",

}

TY - JOUR

T1 - A comparison of atropine sulfate and metaproterenol sulfate in the emergency treatment of asthma

AU - Karpel, J. P.

AU - Appel, David W.

AU - Breidbart, D.

AU - Fusco, M. J.

PY - 1986

Y1 - 1986

N2 - Twenty-one patients presenting to an emergency room with moderate to severe asthma were entered into the following double-blind, crossover study. First, patients inhaled twice at 30-min intervals either atropine sulfate (AS) (3.2 mg and 3.2 mg; total dose, 6.4 mg) or metaproterenol sulfate (MP) (15 mg and 15 mg; total dose, 30 mg). Then after 80 min (crossover), they inhaled either AS (3.2 mg) or MP (15 mg). FEV1 was measured before treatment and at 30, 40, 70, 80, 110, and 120 min after the start of the study. FEV1 from 20 patients who completed the protocol were compared (Student's paired t test), and the values are presented as mean ± SEM. Both groups began with equally severe airways obstruction (AS versus MP: 1.02 ± 0.07 L and 0.92 ± 0.15 L, respectively; p > 0.05). After 120 min, when all had received both medications, FEV1 had improved significantly and similarly among both groups, indicating that initially they had equivalent bronchodilator capacities. Atropine sulfate produced small but significant changes in FEV1 at 30 and 70 min, but not at 80 min nor after crossover. In contrast, MP both alone and after crossover significantly improved FEV1. The difference in improvement among the groups was significant at 80 min and after crossover. Atopine sulfate produced multiple adverse effects in all patients. We conclude that during acute severe asthma, AS (6.4 mg) does not produce clinically significant bronchodilation either alone or in combination with MP.

AB - Twenty-one patients presenting to an emergency room with moderate to severe asthma were entered into the following double-blind, crossover study. First, patients inhaled twice at 30-min intervals either atropine sulfate (AS) (3.2 mg and 3.2 mg; total dose, 6.4 mg) or metaproterenol sulfate (MP) (15 mg and 15 mg; total dose, 30 mg). Then after 80 min (crossover), they inhaled either AS (3.2 mg) or MP (15 mg). FEV1 was measured before treatment and at 30, 40, 70, 80, 110, and 120 min after the start of the study. FEV1 from 20 patients who completed the protocol were compared (Student's paired t test), and the values are presented as mean ± SEM. Both groups began with equally severe airways obstruction (AS versus MP: 1.02 ± 0.07 L and 0.92 ± 0.15 L, respectively; p > 0.05). After 120 min, when all had received both medications, FEV1 had improved significantly and similarly among both groups, indicating that initially they had equivalent bronchodilator capacities. Atropine sulfate produced small but significant changes in FEV1 at 30 and 70 min, but not at 80 min nor after crossover. In contrast, MP both alone and after crossover significantly improved FEV1. The difference in improvement among the groups was significant at 80 min and after crossover. Atopine sulfate produced multiple adverse effects in all patients. We conclude that during acute severe asthma, AS (6.4 mg) does not produce clinically significant bronchodilation either alone or in combination with MP.

UR - http://www.scopus.com/inward/record.url?scp=0022654914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022654914&partnerID=8YFLogxK

M3 - Article

VL - 133

SP - 727

EP - 729

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 5

ER -